GO:0005133 type II interferon receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005133 describes the molecular function of binding to a type II interferon receptor, where type II interferon is interferon-gamma (IFN-γ).
• IFN-γ is a dimeric cytokine that engages the IFNGR1/IFNGR2 receptor complex to trigger JAK-STAT signaling and antimicrobial, antiviral, and immunomodulatory responses.
• Type II interferon receptor binding is distinct from type I interferon receptor binding, although both cytokine-receptor systems share structural and signaling principles.
• Functional characterization of type II interferon receptors has been performed in diverse vertebrate models, including Japanese eel and Nibea albiflora, revealing conserved ligand-receptor interactions.
• Dysregulated IFN-γ signaling is implicated in autoimmune diseases such as psoriasis and in cancer immunology, making this GO term relevant to human disease research.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of genes mediating type II interferon receptor binding and downstream responses.
Description
Type II interferon receptor binding (GO:0005133) is a molecular function defined as binding to a type II interferon receptor, where type II interferon is also known as interferon-gamma (IFN-γ). This function is executed by IFN-γ and related ligands that physically associate with the receptor complex composed of IFNGR1 and IFNGR2, initiating signal transduction cascades that control immune defense and cellular homeostasis. The term is a critical node in cytokine-receptor interaction networks and is frequently annotated in studies of host-pathogen interactions and immune regulation. Researchers study GO:0005133 to understand how IFN-γ recognizes its receptor and how this interaction translates into biological outcomes such as antiviral activity, macrophage activation, and major histocompatibility complex (MHC) regulation. The binding event is the first committed step in type II interferon signaling, and its specificity determines which cells respond to IFN-γ in a given tissue microenvironment. Because IFN-γ signaling is conserved across vertebrates, comparative studies in fish and mammals have provided insights into the structural determinants of receptor binding and activation. From a translational perspective, the type II interferon receptor binding function is linked to autoimmune pathology, cancer immunosurveillance, and inflammatory diseases. Experimental models that perturb this binding event, such as receptor knockouts or ligand mutations, are essential for establishing causality and for evaluating therapeutic strategies targeting the IFN-γ axis. This article integrates the QuickGO definition with verified literature to provide a research-grade overview of GO:0005133, its mechanisms, key genes, and methods for functional interrogation.
type II interferon receptor binding At A Glance
| GO ID | GO:0005133 |
|---|---|
| GO term | type II interferon receptor binding |
| Ontology | molecular_function |
| Synonym | interferon-gamma receptor binding; interferon-gamma receptor ligand |
| Definition | Binding to a type II interferon receptor. Type II interferon is also known as interferon-gamma. |
| Major function | Mediates IFN-γ recognition of its receptor to initiate JAK-STAT signaling and immune responses. |
| Related ligand | Interferon-gamma (IFN-γ), a dimeric cytokine. |
| Related receptors | IFNGR1 and IFNGR2 subunits form the type II interferon receptor complex. |
| Taxonomic scope | Conserved in vertebrates; experimentally characterized in mammals and teleost fish. |
What Is GO:0005133?
GO:0005133, type II interferon receptor binding, is the molecular function of selectively interacting with a type II interferon receptor. Type II interferon is interferon-gamma (IFN-γ), a cytokine that binds to its cognate cell surface receptor complex to initiate signaling. This function is attributed to the ligand (IFN-γ) or to any protein that directly binds the type II interferon receptor as part of a receptor-ligand interaction. The term is a child of cytokine receptor binding and is distinct from type I interferon receptor binding, which involves interferons alpha and beta. In practice, annotation of GO:0005133 requires experimental evidence of physical binding to a type II interferon receptor, such as co-immunoprecipitation, surface plasmon resonance, or functional receptor activation assays.
Why Is type II interferon receptor binding Important in Cell Biology?
Type II interferon receptor binding is a central molecular event in immune signaling because it determines whether a cell responds to IFN-γ, a cytokine critical for host defense against intracellular pathogens and for tumor immunosurveillance. The specificity and affinity of this binding interaction regulate the magnitude and duration of downstream JAK-STAT activation, which in turn controls gene programs involved in antigen presentation, macrophage polarization, and cell growth inhibition. Dysregulation of IFN-γ receptor binding has been associated with autoimmune conditions such as psoriasis and with cancer progression, underscoring its clinical relevance. Consequently, understanding the structural and functional basis of GO:0005133 is essential for immunology, infectious disease, and oncology research.
• Defines the first step in type II interferon signaling, enabling IFN-γ-mediated immune activation.
• Controls antiviral and antimicrobial responses through JAK-STAT pathway activation.
• Regulates MHC class I and II expression, influencing antigen presentation to T cells.
• Implicated in autoimmune diseases such as psoriasis, where IFN-γ signaling contributes to inflammation.
• Plays a role in cancer immunosurveillance and response to immunotherapy.
• Provides a target for therapeutic modulation of IFN-γ activity in inflammatory and neoplastic diseases.
• Conserved across vertebrates, allowing comparative studies in fish models to inform receptor-ligand evolution.
• Enables functional annotation of uncharacterized interferon receptors in non-model organisms.
• Supports development of soluble receptor decoys or blocking antibodies that interfere with binding.
• Facilitates CRISPR-based screens to identify modifiers of IFN-γ receptor binding and signaling.
Molecular Mechanism of type II interferon receptor binding
Ligand recognition and receptor engagement
In simple terms: IFN-γ grabs onto its receptor on the cell surface, like a key fitting a lock.
Type II interferon receptor binding begins when the IFN-γ dimer recognizes and binds to the extracellular domain of IFNGR1, the primary ligand-binding subunit of the receptor complex. This interaction is highly specific and is mediated by conserved residues on IFN-γ that form a binding interface with IFNGR1. In Nibea albiflora, IFN-γ and IFNGR1 were identified and functionally characterized, demonstrating direct binding and activation of downstream signaling. Similarly, in Japanese eel, three type II interferon receptor homologs (CRFB6, CRFB13, and CRFB17) were shown to bind IFN-γ and trigger antiviral responses. These studies confirm that the binding event is conserved across divergent vertebrate lineages.
Receptor complex assembly and conformational change
In simple terms: After the first receptor grabs IFN-γ, a second receptor joins in to form a complete signaling unit.
Following initial IFN-γ binding to IFNGR1, the complex recruits IFNGR2, forming a functional heterodimeric receptor assembly. This assembly step is essential for bringing the intracellular domains of the receptor subunits into proximity, allowing associated JAK kinases to trans-phosphorylate and initiate signaling. Structural studies of type I interferon receptor complexes have revealed that ligand binding induces specific conformational changes that promote receptor oligomerization. Although type II interferon receptor binding is distinct, it shares the principle that ligand-induced receptor assembly is a prerequisite for signal transduction.
JAK-STAT activation and signal propagation
In simple terms: The assembled receptor turns on enzymes inside the cell that carry the signal to the nucleus.
Once the type II interferon receptor complex is assembled, JAK1 and JAK2 kinases associated with IFNGR1 and IFNGR2 become activated and phosphorylate STAT1. Phosphorylated STAT1 forms dimers that translocate to the nucleus and drive transcription of IFN-γ-responsive genes. This canonical JAK-STAT pathway is the principal downstream output of type II interferon receptor binding, and its dysregulation can lead to immune pathology. The binding affinity and kinetics of IFN-γ to its receptor influence the strength and duration of STAT1 activation, thereby shaping cellular responses.
Regulation by soluble receptors and decoys
In simple terms: Decoy receptors can soak up IFN-γ and prevent it from reaching the cell surface receptor.
The type II interferon receptor binding function can be modulated by soluble forms of the receptor or by decoy molecules that compete with membrane-bound receptors for IFN-γ. Soluble extracellular domains of interferon receptors have been shown to exhibit antiviral activities by sequestering interferon ligands. This principle suggests that soluble IFNGR1 or IFNGR2 variants could regulate the availability of IFN-γ for receptor binding on target cells. Such regulatory mechanisms are important for fine-tuning immune responses and have therapeutic implications for inflammatory diseases.
Cross-talk with other cytokine signaling pathways
In simple terms: IFN-γ signaling does not act alone; it communicates with other immune signals.
Type II interferon receptor binding and subsequent signaling can cross-talk with other cytokine pathways, including tumor necrosis factor-alpha (TNF-α) signaling. Co-immobilized TNF-α plus IFN-γ has been shown to induce death signal transduction in cancer cells, indicating that combined receptor engagement can synergize to produce enhanced biological effects. This cross-talk highlights the importance of context in interpreting the outcomes of type II interferon receptor binding and suggests that combinatorial targeting may be therapeutically beneficial.
Key Genes Involved in GO:0005133 type II interferon receptor binding
The following genes and proteins are directly involved in type II interferon receptor binding or its downstream signaling, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNG | Encodes interferon-gamma, the ligand that binds type II interferon receptor. | Knockout and overexpression models to study ligand availability and immune activation. |
| IFNGR1 | Primary ligand-binding subunit of the type II interferon receptor complex. | Target for knockout to abolish IFN-γ binding and signaling. |
| IFNGR2 | Accessory subunit required for receptor assembly and signaling. | Knockout models to dissect assembly-dependent signaling. |
| JAK1 | Kinase associated with IFNGR1 that phosphorylates STAT1. | Point mutations to study kinase activation and signaling. |
| JAK2 | Kinase associated with IFNGR2 that participates in signal transduction. | Knockout and inhibitor studies to block IFN-γ signaling. |
| STAT1 | Transcription factor activated downstream of receptor binding. | Knockout models to assess gene expression changes. |
| CRFB6 | Type II interferon receptor homolog in Japanese eel. | Comparative studies of receptor-ligand evolution. |
| CRFB13 | Type II interferon receptor homolog in Japanese eel. | Functional characterization in non-model fish. |
| CRFB17 | Type II interferon receptor homolog in Japanese eel. | Antiviral response studies in aquaculture species. |
| IFNGR1 (Nibea albiflora) | Characterized IFN-γ receptor in marine fish. | Expression pattern and functional analysis. |
| IFN-γ (Nibea albiflora) | Ligand for type II interferon receptor in fish. | Binding assays and immune challenge experiments. |
| TNF-α | Cytokine that cross-talks with IFN-γ signaling. | Combination studies for cancer therapy. |
| Soluble IFNGR1 | Decoy receptor that modulates IFN-γ availability. | Antiviral and immunomodulatory applications. |
| Soluble IFNGR2 | Potential decoy receptor for IFN-γ. | Therapeutic development for inflammatory diseases. |
| IRF1 | Transcription factor induced by IFN-γ signaling. | Downstream readout of receptor activation. |
| SOCS1 | Negative regulator of JAK-STAT signaling. | Feedback regulation studies. |
| PIAS1 | Protein inhibitor of activated STAT1. | Modulation of IFN-γ responses. |
How Is type II interferon receptor binding Regulated?
Type II interferon receptor binding is regulated at multiple levels, including ligand availability, receptor expression, and feedback inhibition. Soluble forms of interferon receptors can compete with membrane-bound receptors for IFN-γ, thereby dampening signaling. Intracellular negative regulators such as SOCS proteins and PIAS proteins attenuate JAK-STAT signaling downstream of receptor engagement. Additionally, cross-talk with TNF-α signaling can modulate the cellular response to IFN-γ. These regulatory mechanisms ensure that IFN-γ responses are tightly controlled in time and space.
type II interferon receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNGR1 | Autoimmune inflammation, cancer immune evasion | Knockout mice or cell lines to assess IFN-γ responses. |
| IFNGR2 | Immunodeficiency, impaired antiviral defense | CRISPR knockout in human cell lines. |
| IFNG | Psoriasis, inflammatory bowel disease | Overexpression or knockout in mouse models. |
| TNF-α | Psoriasis, cancer cell death | Combination treatment in xenograft models. |
| STAT1 | Mendelian susceptibility to mycobacterial disease | Point mutation knock-in to mimic patient variants. |
Autoimmune and inflammatory diseases
Dysregulated type II interferon receptor binding and signaling contribute to autoimmune pathology. In a mouse model of psoriasis, resident T cells and TNF-α were shown to be essential for disease development, and IFN-γ signaling is known to exacerbate inflammatory responses. The interplay between IFN-γ and TNF-α at the receptor level may amplify tissue damage in autoimmune conditions. Targeting the IFN-γ receptor binding interface could therefore offer therapeutic benefit in psoriasis and related disorders.
Cancer immunology
IFN-γ signaling is critical for tumor immunosurveillance, and type II interferon receptor binding on tumor cells can lead to growth inhibition or apoptosis. Co-immobilized TNF-α plus IFN-γ has been shown to induce death signal transduction in cancer cells, suggesting that enhancing receptor binding and downstream signaling may be a strategy for anti-cancer therapy. Conversely, tumors may evade immune responses by downregulating IFNGR1 or IFNGR2, highlighting the clinical importance of this binding event.
Infectious diseases
Type II interferon receptor binding is essential for host defense against intracellular pathogens. Functional characterization of type II interferon receptors in Japanese eel and Nibea albiflora demonstrated their role in antiviral responses. These studies indicate that the binding function is conserved and critical for immunity across vertebrates, and that its impairment can increase susceptibility to infections.
From type II interferon receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IFNGR1 abolish IFN-γ binding and signaling? | IFNGR1 knockout cell line (e.g., HeLa or HEK293T). |
| Which residues of IFN-γ mediate receptor binding? | Point mutations in IFNG followed by binding assays. |
| Can a tagged IFNGR1 be used to track receptor trafficking? | Knock-in of fluorescent or epitope tag at endogenous IFNGR1 locus. |
| Does overexpression of IFNGR2 enhance sensitivity to IFN-γ? | Stable overexpression in IFN-γ-responsive cells. |
| What genes are essential for type II interferon receptor binding? | Genome-wide CRISPR knockout library screening. |
| How does IFN-γ binding affect global gene expression? | RNA-seq after IFN-γ stimulation in wild-type and knockout cells. |
How to Study the type II interferon receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterization of IFN-γ binding to IFNGR1. |
| Co-immunoprecipitation | Physical interaction in cell lysates | Validation of receptor-ligand complexes. |
| Western blot | Phosphorylation of STAT1 | Assessment of downstream signaling. |
| Luciferase reporter assay | Transcriptional activation of IFN-γ target genes | Functional readout of receptor binding. |
| RNA-seq | Global gene expression changes | Identification of IFN-γ-regulated genes. |
| Fluorescence microscopy | Cellular localization and binding dynamics | Visualization of receptor-ligand interaction. |
| Antiviral assay | Protection against viral infection | Functional consequence of receptor binding. |
| CRISPR screening | Identification of genes required for binding | Genome-wide modifier screens. |
Binding assays
Direct measurement of type II interferon receptor binding can be performed using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or enzyme-linked immunosorbent assay (ELISA) with recombinant IFN-γ and receptor ectodomains. These methods provide quantitative affinity constants and kinetic parameters. Co-immunoprecipitation of IFN-γ with IFNGR1 from cell lysates can confirm physical interaction in a cellular context.
Functional assays
Downstream signaling events can be monitored by Western blot for phosphorylated STAT1 or by luciferase reporter assays driven by IFN-γ-responsive promoters. Antiviral activity assays, such as protection against viral infection, provide a functional readout of receptor binding and signaling. These assays are essential for linking binding to biological outcomes.
Transcriptomics and proteomics
RNA sequencing (RNA-seq) after IFN-γ stimulation reveals global gene expression changes mediated by receptor binding. Proteomic approaches such as mass spectrometry can identify proteins that associate with the receptor complex upon ligand binding. These high-throughput methods help define the broader signaling network activated by type II interferon receptor binding.
Imaging and localization
Fluorescence microscopy and live-cell imaging can visualize the interaction between fluorescently tagged IFN-γ and its receptor on the cell surface. Total internal reflection fluorescence (TIRF) microscopy is particularly useful for studying binding events at the plasma membrane. These techniques provide spatial and temporal resolution of receptor engagement.
How CRISPR Can Be Used to Study GO:0005133 type II interferon receptor binding
Knockout
CRISPR knockout of IFNGR1, IFNGR2, or IFNG can completely abolish type II interferon receptor binding and downstream signaling, providing a clean genetic model to study loss-of-function phenotypes. Knockout cell lines are valuable for confirming the specificity of binding assays and for identifying compensatory pathways. In vivo knockout models can reveal the role of receptor binding in immune responses and disease progression.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can be used to dissect the binding interface between IFN-γ and its receptor. For example, mutating specific residues in IFNGR1 that are predicted to contact IFN-γ can test their contribution to binding affinity and signaling. Such models are essential for understanding structure-function relationships and for mimicking patient-derived mutations.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) at the endogenous IFNGR1 or IFNGR2 locus allows real-time tracking of receptor expression, localization, and binding dynamics without overexpression artifacts. Tagged knock-in models are also useful for proteomic analysis of receptor complexes. These models facilitate precise interrogation of type II interferon receptor binding in a physiological context.
Overexpression
Overexpression of IFN-γ or its receptor subunits can enhance sensitivity to type II interferon signaling and is useful for studying gain-of-function effects. Overexpression models can be used to test whether increased receptor availability leads to stronger or prolonged signaling. However, careful controls are needed to distinguish overexpression artifacts from physiological regulation.
How EDITGENE Supports type II interferon receptor binding Research
Researchers studying type II interferon receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor assembly, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of genes associated with GO:0005133.
Contact EDITGENE today to design your custom CRISPR model for type II interferon receptor binding research.
Frequently Asked Questions About type II interferon receptor binding
What is type II interferon receptor binding?
Type II interferon receptor binding (GO:0005133) is the molecular function of binding to a type II interferon receptor, where type II interferon is interferon-gamma (IFN-γ).
What genes are involved in type II interferon receptor binding?
Key genes include IFNG (encoding IFN-γ), IFNGR1 and IFNGR2 (receptor subunits), and downstream signaling molecules such as JAK1, JAK2, and STAT1.
What is the difference between type I and type II interferon receptor binding?
Type I interferon receptor binding involves interferons alpha and beta, while type II interferon receptor binding specifically involves interferon-gamma and its cognate receptor complex.
How does IFN-γ bind to its receptor?
IFN-γ binds to the extracellular domain of IFNGR1, which then recruits IFNGR2 to form a signaling-competent complex that activates JAK-STAT signaling.
What diseases are associated with type II interferon receptor binding?
Dysregulation of this binding is linked to autoimmune diseases such as psoriasis, cancer immune evasion, and increased susceptibility to infections.
What research methods are used to study type II interferon receptor binding?
Common methods include surface plasmon resonance, co-immunoprecipitation, Western blot for STAT1 phosphorylation, RNA-seq, and CRISPR-based genetic screens.
Can CRISPR be used to study type II interferon receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of genes involved in this binding event.
What are the synonyms for type II interferon receptor binding?
Synonyms include interferon-gamma receptor binding and interferon-gamma receptor ligand.
Which GO term describes type II interferon receptor binding?
The exact GO ID is GO:0005133, with the official name type II interferon receptor binding.
Why is type II interferon receptor binding important for immunology?
It initiates IFN-γ signaling, which is essential for antiviral and antimicrobial immunity, antigen presentation, and tumor immunosurveillance.
Conclusion
Type II interferon receptor binding (GO:0005133) is a fundamental molecular function that governs cellular responses to IFN-γ. Through precise ligand-receptor interactions, it activates JAK-STAT signaling and orchestrates immune defense, inflammation, and cell growth control. Dysregulation of this binding event is implicated in autoimmune diseases and cancer, making it a compelling target for therapeutic intervention. Advances in CRISPR-based genome editing now allow researchers to systematically dissect the genes and mechanisms underlying this function, paving the way for new discoveries and clinical applications.
References
- 1. Tang X et al.. 2007. Acetylation-dependent signal transduction for type I interferon receptor.. Cell 131(1):93-105 PMID: 17923090
- 2. Li Z et al.. 2008. The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling.. J Mol Biol 377(3):715-24 PMID: 18252254
- 3. Su S et al.. 2026. Identification and functional characterization of type II interferon receptors (CRFB6, CRFB13 and CRFB17) in Japanese eel (Anguilla japonica).. Fish Shellfish Immunol 177:111594 PMID: 42456868
- 4. Liu Y et al.. 2024. Identification, functional characterization and expression pattern of interferon-gamma (IFN-γ) and interferon-gamma receptor 1 (IFNGR1) in Nibea albiflora.. Fish Shellfish Immunol 144:109274 PMID: 38072135
- 5. Han CS et al.. 2001. Antiviral activities of the soluble extracellular domains of type I interferon receptors.. Proc Natl Acad Sci U S A 98(11):6138-43 PMID: 11344274
- 6. Boyman O et al.. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.. J Exp Med 199(5):731-6 PMID: 14981113
- 7. Guan YQ et al.. 2010. Death signal transduction induced by co-immobilized TNF-α plus IFN-γ and the development of polymeric anti-cancer drugs.. Biomaterials 31(34):9074-85 PMID: 20832854
